ESMO 2023 highlights: advances in EGFR+ lung cancer second-line therapy

ESMO 2023 Lung Cancer Highlights – Keynote 671 | ALINA | TropionLung01 | Oncology BrothersПодробнее

Highlights on amivantamab after progression on osimertinib in EGFR-mutated NSCLC: MARIPOSA-2Подробнее

AACR 2023 highlights on advances in the neoadjuvant treatment of resectable NSCLC with John HeymachПодробнее

ESMO 2023 highlights in genitourinary cancerПодробнее

Lung cancer highlights from ESMO 2022Подробнее

Phase III MARIPOSA: amivantamab + lazertinib vs osimertinib in EGFR-mutated NSCLCПодробнее

Highlights on datopotamab deruxtecan in advanced NSCLC: The TROPION-Lung01 studyПодробнее

Highlights in lung cancer at ESMO 2022Подробнее

ASCO 2023 Expert Report on novelties in oncogene driven NSCLC by A. Curioni-FontecedroПодробнее

ESMO highlights: KRAS G12C inhibitorsПодробнее

Therapeutic strategies for EGFR-mutated lung cancerПодробнее

Consolidation therapy for unresectable stage III EGFR-mutant NSCLCПодробнее

2023 Best of Lung: Targeted Therapies in Lung CancerПодробнее

Dr Jänne on Second-Line Treatment Evolutions in EGFR-Mutated NSCLCПодробнее

AACR 2023 highlights on advances in the treatment of hepatocellular carcinoma with Pierce ChowПодробнее

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positi...Подробнее

Highlights in gynecological cancers at ESMO 2023Подробнее

EGFR mutation positive tumors: Treatment strategies in front line and at relapseПодробнее

2021 West Oncology | Lung Cancer | EGFR Mutation Therapy Resistance and ADCs and TROP2Подробнее